How Often Do You Have to Take Allergy Shots? Adherence Guide

Real-world adherence data shows only 50-70% of allergy shot patients complete 3 years of treatment. When the target is the recommended 3-5 year full course, completion rates fall even lower — some studies report as few as 23% of patients completing the full recommended duration. Kiel et al. (JACI 2013) found the steepest discontinuation occurs between months 6-18, often right after the transition from weekly build-up to monthly maintenance. At this point, many patients feel enough symptom improvement to rationalize stopping, not realizing that the most significant long-term disease modification accumulates during continued maintenance. Patients who completed fewer than 2 years show substantially less lasting benefit than 3-year completers.

Missing a week of allergy shots during the build-up phase — a gap of more than 7 days — requires a dose reduction before resuming. Per Cox et al. (JACI 2011), the standard protocol is to reduce the next dose by approximately 50% and re-escalate from that point. This dose reduction is a safety measure: your immune system's recent tolerance of higher doses needs to be reassessed after a gap. The practical consequence is that your build-up timeline extends by 2-4 weeks per missed dose. If you missed 2 or more weeks in a row during build-up, you may need to return to a lower vial concentration. Always contact your allergist's office before your next appointment after a gap so they can prepare the correct dose.

Scheduling burden is the most commonly cited reason patients discontinue allergy shots prematurely. The weekly build-up visit schedule combined with the mandatory 30-minute post-injection observation period requires approximately 50-60 hours of clinic time in year one alone. Mahdi et al. (AAIR 2020) identified that 23% of patients take paid time off work for injections. Cost barriers also contribute — patients with higher copays show 20-30% lower completion rates. Other common barriers include holiday travel conflicts, new employment with different schedules, insurance changes, and the misperception that partial improvement means the treatment has worked and can be stopped. Patient education specifically focused on the disease-modification goal — not just symptom relief — improves completion rates.

Evidence-based adherence strategies can meaningfully improve completion rates. Mahdi et al. (AAIR 2020) found that appointment reminders — phone, text, or email — increased adherence by approximately 12%. Practices offering flexible scheduling, including evening and weekend hours, saw adherence improve by 18%. Early patient education specifically explaining the disease-modification goal — that the benefit accumulates over 3-5 years, not just as symptom relief — was associated with a 15% adherence improvement. Newer approaches include telemedicine check-ins between injection visits to reinforce the rationale for continuing. Some practices have also experimented with consolidated visit days where patients receive both their injection and follow-up allergy consultation on the same visit, reducing total clinic time per year.

Yes — consistently missing doses reduces the disease-modifying effect of allergy shots. Eng et al. (Clin Exp Allergy 2006) found that patients who completed fewer than 2 years of SCIT showed significantly less disease modification than patients completing 3+ years. The disease modification from allergy shots is not an all-or-nothing effect — it accumulates over time — but there is a dose-response relationship between treatment duration and lasting benefit. Patients who completed 3 years have markedly better long-term outcomes than those who stopped at 2 years. Those who stop before 18 months often see complete symptom return within a year of stopping, similar to having received no treatment. Maintaining consistent dosing, especially through the critical months 6-24, is the single most important factor in whether a patient gets full benefit.

Yes, allergy shots can be restarted after a long break, but the restart protocol depends on how long you stopped and how much treatment you had completed before stopping. If you stopped for 3 months or more, your allergist will likely perform a skin test reassessment to determine your current sensitization level and plan an appropriate re-escalation. Patients who completed a year or more before stopping often retain partial tolerance and may be able to restart at an intermediate concentration rather than from the very beginning. A vial test — administering a reduced dose and observing for 30 minutes — is typically required before returning to the maintenance dose. The good news: any disease modification already established is not completely lost, and restarting can continue building on that foundation.

The most common time patients discontinue allergy shots is between months 6 and 18 — immediately after transitioning from the weekly build-up schedule to monthly maintenance. This timing is counterintuitive but consistently documented in adherence research. During build-up, patients are highly engaged: weekly visits, noticeable dose escalation, and usually an improvement in symptoms as the maintenance dose is approached. Once maintenance begins, the visit schedule lightens and symptom improvement may plateau or seem 'good enough,' leading patients to underestimate the ongoing disease-modification process still occurring. Kiel et al. (JACI 2013) and other cohort studies confirm this 6-18 month window as the highest-risk period for dropout, which is why patient education at the start of maintenance is particularly important.